HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Listerine With Fluoride Proposed Six-Month Study To Be Reviewed By FDA

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product

You may also be interested in...



FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA

A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over the control to receive agency approval, FDA told Pfizer execs at an Aug. 27 meeting

Listerine meeting postponed

"Feedback" meeting on Pfizer's proposed changes to the OTC anticaries final monograph, originally slated for June 18, will be rescheduled within a month to give Division of OTC Drug Products more time to review relevant material, FDA says June 14. Meeting is part of Pfizer's efforts to amend monograph to allow for a mouthrinse combining essential oils, sodium fluoride (1"The Tan Sheet" June 10, 2002, p. 3)...

W-L Listerine Anticaries Rinse Gingivitis Assessment Required - FDA

Acceptance of plaque reduction as the sole outcome of an experimental gingivitis model conducted to demonstrate the antiplaque/antigingivitis activities of Pfizer/Warner-Lambert's Listerine anticaries mouthrinse would be "premature," FDA tells company.

Related Content

Topics

UsernamePublicRestriction

Register

RS130062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel